Vista (deficiente)

ALA deficiency impairs skin barrier function and is linked to atopic dermatitis. ALA derivatives modulate epidermal immune responses by influencing T lymphocytes and Toll-like receptors, with relevance to inflammatory dermatoses including atopic dermatitis.

Allantoin-containing creams have been evaluated in diaper dermatitis in a randomized controlled trial, showing significant reduction of erythema and lesion scores comparable to low-potency steroids. In radiation-induced dermatitis, allantoin-containing emulsions improved skin healing and reduced discomfort. Its keratolytic, anti-inflammatory, and barrier-restoring properties are mechanistically relevant to multiple dermatitis subtypes.

Aloe vera has been studied for atopic and radiation-induced dermatitis. Systematic reviews and clinical trials have investigated its topical application for radiation dermatitis prevention, with some positive signals; evidence for atopic dermatitis is mixed. Its polysaccharides exhibit anti-inflammatory and barrier-supportive properties.

Artepillin C is the principal bioactive polyphenol of Brazilian green propolis (from Baccharis dracunculifolia). It inhibits NF-κB, COX-2, and pro-inflammatory cytokines relevant to dermatitis. Brazilian propolis preparations containing artepillin C have been studied in inflammatory skin conditions.

Indigo Naturalis oil extract (Lindioil) from S. cusia has been evaluated in randomized clinical trials for atopic dermatitis (AD). Both a double-blind placebo-controlled RCT and a crossover evaluator-blinded RCT showed significant EASI score reductions. Traditional use for 'eczema, impetigo' and facial eczema in infants is also documented.

Bee propolis has been evaluated in atopic dermatitis studies, including as part of propolis-tea tree oil-aloe vera cream (PTAC) formulations. Its polyphenols and artepillin C inhibit NF-κB and inflammatory mediators. Traditional use for skin inflammation is ancient and cross-cultural.

Bifidobacterium species (particularly breve and longum) have been studied in multiple RCTs for atopic dermatitis. A meta-analysis found Bifidobacterium and Lactobacillus consumption was associated with 'significant improvements in disease management.' A combination including B. breve was among the most studied.

Bifidobacterium bifidum has been studied in clinical trials for atopic dermatitis, including in pediatric populations. Systematic reviews on probiotics in AD include B. bifidum strains among those tested, with evidence for immunomodulatory effects on the Th2-skewed immune response in AD.

Bifidobacterium breve has been studied in RCTs for atopic dermatitis prevention and treatment, particularly in infants and children. It is included in multiple systematic reviews of probiotics for AD and has demonstrated immunomodulatory effects relevant to the Th2-biased inflammation of AD.

Bifidobacterium longum has been specifically studied in RCTs for atopic dermatitis. A combination of B. longum CECT 7347 with other probiotic strains was shown to reduce SCORAD values and topical steroid use in moderate AD. It is among the most-studied Bifidobacterium species for AD.

Betulin (the main triterpene in birch bark) has demonstrated activity in normalising disrupted skin function in atopic dermatitis contexts. A study on Betula platyphylla bark in a mouse model of atopic dermatitis-like lesions showed inhibition of skin inflammation. Birch water is documented for topical use in dermatitis. Oleogel-S10 clinical data provides evidence of birch bark's anti-inflammatory and skin-normalising effects.

Black seed (Nigella sativa) oil has clinical evidence for eczema/hand dermatitis, with one clinical trial showing equal efficacy to betamethasone cream for hand eczema. Its active thymoquinone exhibits potent anti-inflammatory properties. It is also under investigation for radiation-induced dermatitis prevention.

Atopic dermatitis (eczema) is the condition most studied for borage oil, with multiple RCTs and a systematic review providing scientific evidence. For contact dermatitis specifically, borage oil's anti-inflammatory GLA activity and barrier-repair properties provide mechanistic support, though direct RCT evidence in contact dermatitis is less specific.

Multiple RCTs of oral and topical borage oil for atopic dermatitis have been conducted, with mixed results. A 2010 review identified 12 clinical trials; five showed significant benefit, five showed no significant benefit, and two showed mixed results. A large RCT (n=151) found no significant benefit of oral GLA over placebo. Topical application shows more consistent promise, including barrier repair and reduction of transepidermal water loss.

Boswellia (olibanum/frankincense) resin has clinical evidence for inflammatory dermatoses. A 200-patient study for psoriasis-related dermatitis found significant PASI reduction with an AKBA-containing ointment. Traditional use in Greco-Roman medicine for skin disorders is well-documented. Anti-inflammatory mechanisms center on 5-lipoxygenase and NF-κB inhibition.

Boswellic acids (from Boswellia/olibanum) have been tested in a 200-patient open-label study for psoriasis (a related inflammatory dermatosis), with significant PASI reduction and reduced inflammatory biomarkers. Boswellia preparations have also been studied for allergic dermatitis, with anti-inflammatory activity documented in animal models.

Calendula officinalis has clinical and preclinical evidence for anti-inflammatory effects relevant to dermatitis. A study in over 250 patients found topical calendula cream superior to trolamine for radiation dermatitis prevention. For diaper dermatitis, at least one RCT found significant benefit. Evidence in atopic dermatitis is limited but traditional use is extensive.

Camellia sinensis (green and black tea) has clinical evidence via its EGCG fraction for radiation-induced dermatitis in breast cancer patients (2:1 RCT in 165 patients showing delayed onset and reduced severity). Black tea tannins from Camellia sinensis have ancient empirical use in dermatology for inflammatory skin conditions.

A 2019 study (Toxicological Research) demonstrated that C. camphora leaf extract alleviated atopic dermatitis in mice by reducing IgE, lymph node inflammation, and chemokine production. The 2024 MDPI review confirmed dermatitis among camphor's documented skin applications. Camphor's anti-inflammatory and antipruritic properties underlie this relationship.

Ceramides are skin barrier lipids critically deficient in atopic dermatitis. Topical ceramide-containing moisturizers are clinically established treatments for AD, supported by evidence reviewed by the FDA, AAD, and multiple clinical trials showing reduction in TEWL and improved skin barrier function.

Chamomile (Matricaria chamomilla) has anti-inflammatory and skin-soothing properties linked to its active bisabolol and chamazulene constituents. Clinical evidence includes a trial showing chamomile cream with mild superiority over 0.5% hydrocortisone cream for atopic dermatitis. Preclinical studies confirm inhibition of allergic inflammatory mediators.

Chickweed is used in both traditional Chinese medicine and Western herbalism for dermatitis, with in vitro studies on human skin cells supporting an antioxidant-based anti-inflammatory mechanism. It is one of chickweed's best-documented applications.

Chrysanthemum flavonoids suppress NF-κB and COX-2 pathways in keratinocytes relevant to atopic dermatitis, and a 2025 PMC network pharmacology and machine learning study identified PTGS2 and MMP9 as core targets. TCM also documents topical use for skin redness and eczematous rashes.

Level 1 RCT evidence supports topical VCO for mild-to-moderate atopic dermatitis in children and adults. WHAM assigned Level 1 evidence for dermatitis. A SCORAD-assessed RCT in pediatric AD found VCO superior to mineral oil at 8 weeks. VCO reduces TEWL, improves skin hydration, and reduces S. aureus colonization.

Coconut oil has clinical evidence for atopic dermatitis. A randomized double-blind trial in mild-to-moderate pediatric AD found virgin coconut oil significantly improved SCORAD index and reduced TEWL compared to mineral oil. Lauric acid provides antimicrobial activity against S. aureus, a key AD-aggravating pathogen.

Curcumin (from turmeric) has been evaluated in multiple dermatological RCTs. A systematic review of 18 RCTs found curcumin showed Grade B recommendation for psoriasis and pruritus, and Grade C-D for radiation dermatitis. It inhibits NF-κB and pro-inflammatory cytokines. Evidence for radiation dermatitis is specifically noted in clinical literature.

Oral d-alpha tocopherol has demonstrated clinical benefit in atopic dermatitis in a controlled study, reducing disease severity and serum IgE levels. It has also been studied in subcorneal pustular dermatoses and other inflammatory skin conditions, with evidence supporting its use as an adjunct therapy.

DHA (from fish oil) has been studied as part of omega-3 supplementation in atopic dermatitis. Anti-inflammatory mechanisms via prostaglandin/leukotriene modulation are well-established. Clinical evidence when studied as part of fish oil in AD is inconsistent per AAD/NCCIH guidelines, though biological rationale is robust.

EGCG, the principal catechin of green tea, has clinical evidence for radiation-induced dermatitis from multiple trials, including a 2:1 randomized controlled study in 165 breast cancer patients where topical EGCG spray delayed onset of radiodermatitis by 2–3 weeks and significantly reduced severity. It is also studied for atopic and seborrheic dermatitis.

Alantolactone from elecampane has been studied in vitro and in animal models for dermatitis-related inflammatory skin conditions. A 2021 PMC-indexed study demonstrated it attenuates psoriasis-like skin lesions in a mouse model by suppressing keratinocyte hyperproliferation and inflammatory cytokines via STAT3 and NF-κB inhibition. A murine atopic dermatitis model using elecampane sesquiterpene lactones has also been published.

EPA (from fish oil) contributes anti-inflammatory effects in atopic dermatitis via competitive inhibition of arachidonic acid metabolism, reducing PGE2 and LTB4. RCTs of EPA+DHA-containing fish oil in AD show modest, inconsistent improvements. Biological rationale is well-supported; clinical evidence is rated inconsistent by AAD guidelines.

Evening primrose oil (EPO) is a rich source of gamma-linolenic acid (GLA) and has been the subject of numerous clinical trials in atopic dermatitis. One RCT found 96% improvement in EPO-treated patients vs. 32% in placebo. A pediatric systematic review noted some indication of efficacy in children. Results across trials are inconsistent.

Topical parthenolide-depleted feverfew (PD-Feverfew) has been tested in controlled studies for skin inflammation. In vivo, PD-Feverfew reduced oxazolone-induced dermatitis by 52–70%, and clinical trials confirmed it did not elicit allergic responses in 1,200 subjects. It is used as a topical anti-inflammatory cosmetic ingredient.

Fish oil (containing EPA and DHA) has been studied in multiple RCTs for atopic dermatitis, showing modest but inconsistent improvements in pruritus and affected surface area. The AAD and NCCIH note inconsistent evidence. Anti-inflammatory mechanisms via eicosanoid modulation are well-established.

A PLoS ONE animal study (2016) demonstrated that Forsythia suspensa extract suppressed house dust mite-induced atopic dermatitis in NC/Nga mice, reducing IgE, TNF-α, histamine, and inflammatory chemokines. The active constituents forsythiaside, phillyrin, pinoresinol, and phylligenin were identified as mediating chemokine suppression in human keratinocytes. Evidence is preclinical; no human RCTs have been conducted.

A human skin study (PubMed 17026651) tested topical Poria cocos in three concentrations in a 4-day repetitive SLS-irritation model for irritant contact dermatitis (ICD), finding statistically significant anti-inflammatory activity by chromametry and transepidermal water loss. Triterpenoids also inhibited induced dermatitis in animal models via PLA2 inhibition.

Gardenia jasminoides extract ameliorates atopic dermatitis in preclinical models by restoring skin barrier function and suppressing Th2-mediated immune overactivation. Genipin inhibits T cell activation via ORAI1 channel modulation, reducing allergic inflammation. These findings support a mechanistic basis for gardenia's traditional use in inflammatory skin conditions.

Gamma-linolenic acid (GLA), the active component of evening primrose and borage oils, has been studied for atopic dermatitis based on the theory of impaired delta-6-desaturase activity in AD patients. Clinical trial results are mixed, with modest improvements in some studies but no significant benefit in others.

A published peer-reviewed study (PMID 20230179) demonstrated that G. littoralis extract significantly reduced TPA-induced acute and chronic skin inflammation in mice, reducing edema, cytokine levels, and MPO activity. A second study confirmed skin inflammation reduction. These findings directly support a dermatitis-related effect.

Glucosylceramide (glucocerebrosides) serve as precursors to skin ceramides and have been studied as oral and topical supplements for restoring the impaired ceramide-dependent skin barrier in atopic dermatitis. Plant-derived glucosylceramides show clinical evidence for improving skin barrier function and reducing dermatitis symptoms.

Glycyrrhetinic acid, the active aglycone of glycyrrhizin from licorice root, inhibits 11β-HSD and leukotriene synthesis and has clinical evidence for anti-inflammatory effects in dermatitis comparable to topical hydrocortisone in some preparations.

Glycyrrhizin, the principal triterpene glycoside of licorice root, inhibits 11β-HSD and leukotriene synthesis, producing anti-inflammatory and corticosteroid-mimicking effects. Topical preparations containing glycyrrhizin have been shown in clinical studies to match hydrocortisone 1% cream in anti-inflammatory efficacy for skin conditions including dermatitis.

Scientific evidence from preclinical and in vitro studies demonstrates that Gotu Kola reduces key inflammatory mediators in atopic dermatitis, including TNF-α, IgE, IL-4, and IL-13. Topical triterpene preparations inhibit inflammatory cell infiltration and mast cell proliferation in dermatitis models. Traditional use across Asian medicine specifically includes dermatitis and inflammatory skin eruptions.

Green tea extract, particularly EGCG, has clinical evidence for radiation-induced dermatitis from RCTs in breast cancer patients, where topical application delayed radiodermatitis onset by 2–3 weeks and reduced severity. Green tea tannins are also recognized in dermatological practice for anti-inflammatory skin effects.

Honey, particularly manuka honey (from Leptospermum scoparium), has clinical and mechanistic evidence for atopic dermatitis. A clinical and cellular study found manuka honey was potentially effective for AD lesions, significantly downregulating IL-4-induced CCL26 from keratinocytes and inhibiting mast cell degranulation. Traditional use spans millennia.

Hyperforin, the principal lipophilic active compound of St. John's Wort, has RCT evidence for atopic dermatitis. A randomized, placebo-controlled, double-blind half-side comparison in 21 AD patients found that 1.5% hyperforin ointment applied twice daily for 4 weeks significantly improved eczematous lesions versus placebo (80% vs. 10% improvement).

Hypericum perforatum (St. John's Wort) has RCT evidence for atopic dermatitis via its hyperforin-rich extract showing 80% improvement vs. 10% in placebo in a double-blind half-side comparison. It has traditional recognition for dermatitis and inflammatory skin disorders across European and official monographs.

H. italicum extracts have been tested in human volunteers for contact dermatitis-type reactions. A supercritical CO2 extract impregnated in textile materials reduced skin erythema, irritation markers, and improved biophysical skin parameters in a randomised in vivo study on artificially irritated human skin.

Impatiens has documented antidermatitic activity in preclinical models. Flavonoids including kaempferol and luteolin inhibit allergic contact dermatitis responses in mice. The topical use of Impatiens juice and extracts for contact dermatitis has also been studied in several human-relevant models.

Linoleic acid (LA, omega-6) is essential for ceramide synthesis and epidermal barrier function, which is impaired in atopic dermatitis. LA-rich oils (sunflower, safflower) support TEWL reduction in dermatitis. Topical LA application is supported in AD management as a barrier-restoring measure.

Multiple Lactobacillus species have been studied in RCTs for atopic dermatitis. A meta-analysis of 14 RCTs in 1,124 children found single-strain lactobacilli significantly reduced SCORAD by a mean difference of −4.50 (p=0.003). Specific strains including L. paracasei K71, L. plantarum, and L. acidophilus L-92 show the strongest evidence.

Lactobacillus acidophilus (particularly strain L-92) has clinical evidence for atopic dermatitis. A systematic review identified L. acidophilus L-92 as able to moderately reduce clinical severity and improve immunological markers in both children and adults with AD.

As atopic dermatitis (AD) and eczema share the same clinical entity (atopic eczema/dermatitis syndrome), the evidence for L. casei in dermatitis is the same body of RCT literature. L. casei strains have been tested in multicenter double-blind RCTs in children with AD, with SCORAD-assessed improvement noted in probiotic groups. Mechanistic work indicates modulation of Th1/IL-10 responses and suppression of pro-allergic cytokines.

Lactobacillus paracasei (especially K71 strain) is specifically identified in systematic reviews as one of the strains with the strongest evidence for reducing AD severity and improving immunological markers. Multiple RCTs support its use in atopic dermatitis in adults.

Lactobacillus plantarum strains (notably IS-10506) have clinical evidence for atopic dermatitis, with studies showing reductions in SCORAD and improvements in immunological markers. It is among the strains identified in systematic reviews as showing meaningful benefit in both children and adults with AD.

Lactobacillus reuteri has been studied in RCTs for atopic dermatitis, including a topical probiotic formulation. A systematic review and meta-analysis of topical probiotics for AD included a study using L. reuteri, contributing to evidence supporting probiotic modulation of AD severity.

Lactobacillus rhamnosus (notably GG strain) is among the most studied probiotic strains for atopic dermatitis. Meta-analyses and systematic reviews document its study in RCTs for both prevention and treatment of AD in children and adults, with modest SCORAD reductions reported in some trials.

L. salivarius LS01 (DSM 22775) is among the best-evidenced single probiotic strains for atopic dermatitis (AD), with multiple RCTs in both children and adults. A randomized placebo-controlled study found L. salivarius LS01 significantly improved SCORAD index in adults with AD after 16 weeks, while a pediatric combination trial showed clinical superiority of L. salivarius plus fructooligosaccharide over FOS alone in children with moderate-to-severe AD.

Lavender essential oil has demonstrated suppressive effects on atopic dermatitis in preclinical research (PubMed PMID 38181031). Network pharmacology studies confirm lavender suppresses TNF-α-mediated skin inflammation and barrier dysfunction relevant to dermatitis. Anti-inflammatory effects via NF-κB pathway inhibition provide mechanistic support. Robust human clinical RCTs specifically for lavender in atopic dermatitis are not yet published.

Topical licorice root preparations have clinical evidence in atopic dermatitis. A double-blind clinical trial in 60 patients found licorice extract gel (1% and 2%) significantly reduced erythema, edema, and itching scores. The active components glycyrrhizin and glycyrrhetinic acid have anti-inflammatory and corticosteroid-mimicking mechanisms.

Luteolin has been reviewed for effects in both atopic dermatitis and contact dermatitis, demonstrating anti-inflammatory and mast cell-stabilizing effects in preclinical models. Topical formulations show promise for reducing dermal inflammation.

A 2021 pilot double-blind RCT found Althaea officinalis 1% ointment improved SCORAD scores in children with atopic dermatitis, performing comparably to hydrocortisone 1%. A second 2021 RCT found liposomal marshmallow extract as effective as topical steroids for atopic eczema. Traditional Persian medicine also extensively documents topical use for skin diseases.

Melaleuca alternifolia (tea tree) oil has clinical evidence for contact dermatitis, particularly nickel-induced contact dermatitis, and antimicrobial/anti-inflammatory effects relevant to seborrheic and atopic dermatitis. It is listed in evidence-based herbal dermatology reviews for treatment of seborrheic dermatitis.

Menthol is a recognized first-line topical treatment for neuropathic and mixed-etiology chronic pruritus, which underlies dermatitis-associated itch. It inhibits both histaminergic and non-histaminergic itch pathways via TRPM8 receptor activation.

M. officinalis extract attenuated atopic dermatitis-like inflammation in a DNCB-induced mouse model via modulation of the MALAT1/miR-590-5p/CCR7 axis. M. citrifolia (fermented noni) also reduced DNCB-induced atopic dermatitis lesions in NC/Nga mice, improving dermatitis scores, immune balance, and skin barrier function. Traditional use of both species for skin inflammation is documented.

Nigella sativa seed has clinical evidence for hand eczema/dermatitis. A clinical trial found N. sativa oil equal in efficacy to betamethasone cream for hand eczema. A systematic review and meta-analysis confirms its therapeutic effects on multiple skin conditions. Active constituent thymoquinone inhibits key inflammatory mediators.

C. rotundus essential oil has anti-inflammatory and antimicrobial properties documented in clinical dermatology studies. Human RCTs have used CREO topically for skin conditions. Its antihistaminic activity (documented preclinically) is particularly relevant to allergic dermatitis.

Colloidal oatmeal (from Avena sativa) is FDA-approved as an OTC skin protectant for eczema/dermatitis. Clinical studies confirm improved skin barrier function, reduced itch, and decreased TEWL in atopic dermatitis patients with 1% colloidal oat-containing moisturizers. It contains avenanthramides with documented anti-inflammatory activity.

Topical olive oil has traditionally been used for dermatitis, including diaper dermatitis. RCT evidence supports olive oil use in contact and diaper dermatitis. However, clinical evidence for atopic dermatitis indicates potential for barrier disruption, while olive oil polyphenols retain anti-inflammatory properties relevant to inflammatory dermatitis.

Omega-3 fatty acids (EPA/DHA) have been studied in multiple RCTs for atopic dermatitis. RCTs showed modest improvements in affected body surface area and pruritus. The American Academy of Dermatology rates the evidence as inconsistent, but a biological rationale via anti-inflammatory eicosanoid production is well-established.

Omega-6 EFAs, particularly GLA and LA, are structurally and functionally essential to normal skin barrier integrity, with deficiencies producing dermatitis-like conditions. Both atopic and contact dermatitis show altered fatty acid profiles, and GLA-rich supplements have clinical evidence in atopic forms. Evening primrose oil did not demonstrate benefit in chronic hand dermatitis in RCTs.

Dietary sea buckthorn oil supplementation (containing omega-7 palmitoleic acid) was shown to alter skin glycerophospholipid fatty acid composition in patients with atopic dermatitis (Yang et al., J Nutr Biochem 2000). This mechanistic human study demonstrates omega-7 incorporation into skin lipids in dermatitis patients. Sea buckthorn oil's anti-inflammatory properties are also relevant to the inflammatory component of dermatitis.

Topical M. aquifolium preparations have been evaluated in clinical trials for both psoriatic and atopic dermatitis, with the Donsky and Clarke (2007) uncontrolled trial and a double-blind herbal combination RCT both showing benefit for atopic dermatitis. The anti-inflammatory, antiproliferative, and antimicrobial alkaloids in Oregon grape mechanistically address key dermatitis pathways.

PABA has FDA approval for dermatomyositis—a skin and muscle autoimmune condition characterized by inflammatory skin involvement. It has also been used for morphea, pemphigus, and lichen sclerosis. Clinical evidence supporting these uses is limited and largely derived from old, uncontrolled studies. Topical PABA itself is a known skin sensitizer that can cause contact dermatitis.

In atopic dermatitis (AD), free and total sapienic acid (POA's isomer) content of non-lesional skin is markedly reduced, correlating with increased S. aureus colonization. POA itself influences IL-37 expression in keratinocytes, supporting an anti-inflammatory role, and POA-rich oils have shown benefit in AD-like models.

Dexpanthenol is clinically established for atopic dermatitis and contact dermatitis. A 2022 PMC evidence review concluded it is effective and well-tolerated for atopic dermatitis, with corticosteroid-sparing effects. Multiple controlled trials demonstrate benefit for irritant and atopic dermatitis, and a 2025 RCT found panthenol ointment non-inferior to mid-potency corticosteroid for chronic hand eczema/dermatitis.

Paeoniflorin has demonstrated anti-inflammatory and anti-allergic effects relevant to contact dermatitis and atopic dermatitis in experimental studies, reducing inflammatory cytokines and MMP-9 in skin cells. Preclinical models support its use as a topical and systemic anti-inflammatory in skin inflammatory conditions.

Topical and systemic rosmarinic acid from Perilla frutescens has demonstrated anti-inflammatory efficacy in atopic and contact dermatitis through multiple mechanisms. Clinical studies confirm improvements in standard dermatitis scores. Preclinical work shows suppression of mast cell activation, IgE production, and skin barrier impairment.

Platycodon root extracts and saponins have demonstrated efficacy in reducing atopic dermatitis-like skin lesions in NC/Nga mouse models, suppressing IgE, Th2 cytokines (IL-4, IgG1), and inflammatory cell infiltration. Both topical and oral routes have been studied. No human RCT for dermatitis with PG alone has been published.

Platycodon root-derived saponins (Changkil saponins, particularly platycodin D) attenuate atopic dermatitis-like skin lesions in multiple mouse models by restoring Th1/Th2 balance and suppressing NF-κB and STAT1 signaling. Traditional texts record platycodon's use for mastitis and dermatitis from the Ming Dynasty. Evidence is preclinical; no human RCT for dermatitis exists.

Propolis (bee propolis) has clinical evidence for atopic dermatitis. Artepillin C and other polyphenols in propolis exhibit anti-inflammatory activity, and propolis-tea tree oil-aloe vera cream (PTAC) has been tested in AD clinical studies. Propolis has traditional use across diverse cultures for inflammatory skin conditions.

A 2023 randomized double-blind placebo-controlled trial (n=70) found oral purslane extract significantly improved fissure, itching, dryness, and composite scores in chronic hand eczema (a form of contact/atopic dermatitis) over 4 weeks. Traditional topical use of purslane for skin inflammation, eczema, and rashes is extensively documented across multiple cultures.

Quercetin has clinical and preclinical evidence for dermatitis. In 10 nickel-sensitive volunteers, oral quercetin (2 g/day for 3 days) reduced nickel-induced contact dermatitis reactions, with 8/10 subjects achieving ≥50% reduction. Animal studies confirm anti-AD activity, and proteomics research is actively investigating its mechanisms in atopic dermatitis.

Rosehip preparations have documented topical benefits for atopic dermatitis (eczema), attributed to anti-inflammatory polyphenols, vitamin C, and essential fatty acids that support the skin barrier. A 2024 systematic review identified rosehip as a candidate agent for treating atopic dermatitis, and its constituents reduce redness and inflammation associated with eczema-type conditions.

A human clinical study demonstrated that topical 0.3% rosmarinic acid emulsion significantly reduced erythema, SCORAD, pruritus, and transepidermal water loss in atopic dermatitis patients over 8 weeks. In vitro and animal models further confirm RA suppresses IgE-mediated and T-cell-driven dermatitis pathways. RA also activates NHE1 to lower skin pH, improving barrier function in inflammatory skin conditions.

Schizonepeta is a principal herb in TCM formulas for allergic and atopic dermatitis, with clinical trial data and multiple animal studies. Controlled human trials of Xiao Feng San (which contains Schizonepeta) for atopic dermatitis, plus direct animal model evidence, support its anti-dermatitic activity.

Shea butter is documented in clinical and traditional contexts for contact and atopic dermatitis. Its barrier-repairing emollient properties reduce TEWL and skin irritant response. The anti-inflammatory triterpene constituents suppress NF-κB-mediated inflammatory signaling. The ethnomedicinal literature records dermatitis as a traditionally treated condition across Sub-Saharan Africa.

SD has been studied in combination with Schizonepeta tenuifolia in an atopic dermatitis mouse model, showing reduction in key dermatitis markers including IgE, TSLP, IL-33, and macrophage TRPV1 expression. The two-herb decoction is rooted in the classical Xiao-feng-San formula for allergic skin diseases. Evidence remains preclinical.

Silymarin has been studied in formulations for atopic dermatitis, with clinical evaluation of organogel formulations documented in the literature. Its mechanisms (NF-κB suppression, TNF-α reduction, antioxidant activity) are relevant to the inflammatory pathophysiology of dermatitis. It is included in cosmetic and therapeutic topical preparations for inflammatory skin conditions.

S. flavescens alkaloids (matrine, oxymatrine) and flavonoids reduce inflammatory markers in contact dermatitis and atopic dermatitis models. Topical Sophora application in mice with contact dermatitis decreased IFN-γ, TNF-α, and inhibited mast cell degranulation. Multiple preclinical studies confirm anti-dermatitic activity.

SPM deficiency has been documented in human dermatitis tissue and serum. SPMs reduce cutaneous inflammatory cytokines and support epithelial barrier repair in human ex vivo models. Both atopic and contact dermatitis show evidence of impaired SPM-mediated resolution.

Squalene is a natural skin lipid whose depletion is associated with barrier dysfunction in dermatitis. Topical squalane is used in clinical and cosmetic practice for atopic dermatitis (eczema) due to its barrier-restoring, anti-inflammatory, and moisturising properties. Anti-inflammatory mechanisms include NF-κB and COX-2 suppression, making it relevant to inflammatory skin conditions.

St. John's Wort (Hypericum perforatum), particularly its hyperforin-rich extracts, has been tested in atopic dermatitis in a randomized, placebo-controlled, double-blind half-side comparison. Patients showed significant improvement in eczematous lesions versus placebo. It is traditionally recognized for dermatitis and inflammatory skin disorders.

Clinical evidence from randomized and controlled trials supports topical S. thermophilus preparations for atopic dermatitis, improving ceramide levels, skin barrier function, and symptom scores including erythema and pruritus. The mechanism involves bacterial sphingomyelinase activity restoring stratum corneum ceramides.

Sulforaphane modulates Nrf2 and NF-κB/MAPK pathways that drive atopic dermatitis pathophysiology, reduces Th2 cytokine-driven barrier dysfunction, and modifies the skin microbiome. The 2026 Nutrients review catalogues SFN as active in atopic dermatitis via these mechanisms. Clinical trials for dermatitis are registered.

Sunflower seed oil and its derivatives show clinical benefit in atopic and contact dermatitis. Its linoleic acid content reduces TNF-alpha and restores defective skin barrier, directly targeting dermatitis pathophysiology. It does not cause irritation or erythema in atopic dermatitis patients.

Sunflower oil (high in linoleic acid) has clinical evidence for atopic dermatitis, improving skin barrier function by reducing TEWL. A systematic review on CAM in dermatology includes sunflower seed oil (SSO) among studied AD interventions. Linoleic acid is essential for ceramide synthesis and skin barrier integrity.

Tea tree oil (Melaleuca alternifolia) has shown clinical benefit in experimentally induced contact dermatitis, reducing dermatitis response to nickel in nickel-sensitive patients. It has anti-inflammatory and antimicrobial properties relevant to seborrheic and atopic dermatitis. However, it may cause allergic contact reactions in some individuals.

Thymoquinone, the principal active constituent of Nigella sativa, inhibits COX, 5-LOX, NF-κB, and TNF-α, providing anti-inflammatory effects relevant to dermatitis. It is specifically under investigation for radiation-induced dermatitis prevention. Animal studies confirm anti-skin inflammatory activity.

Turmeric (Curcuma longa) and its active curcuminoids have been studied in RCTs for dermatitis, psoriasis, and pruritus. Clinical studies show anti-inflammatory effects via NF-κB and cytokine inhibition. A systematic review of 18 RCTs found Grade B evidence for psoriasis and pruritus. Radiation dermatitis is also an area of clinical investigation.

Vitamin A status is measurably altered in atopic dermatitis: skin retinol concentrations are reduced in dermatitis lesions compared to controls. Animal data show vitamin A deficiency exacerbates atopic dermatitis-type inflammation by potentiating Th2 responses and mast cell activation. Topical retinoids are used clinically in certain inflammatory dermatoses.

Riboflavin deficiency classically produces mucocutaneous skin lesions including angular stomatitis, cheilosis, and seborrheic dermatitis-like changes around the nose and scrotum. These lesions reverse with riboflavin repletion. EFSA has formally recognized riboflavin as contributing to the maintenance of normal skin and mucous membranes.

Niacin deficiency itself causes pellagra dermatitis; beyond deficiency correction, topical and oral niacinamide have been studied for atopic dermatitis and seborrheic dermatitis. Topical niacinamide stabilizes the epidermal barrier, reduces transepidermal water loss, and exerts anti-inflammatory effects relevant to eczematous conditions. A 2004 PubMed review confirmed anti-inflammatory effects in irritant and inflammatory skin conditions.

Topical dexpanthenol has been studied as an alternative to mild corticosteroids for atopic dermatitis. A pilot RCT comparing 5% dexpanthenol ointment with 1% hydrocortisone found dexpanthenol can treat mild-to-moderate childhood atopic dermatitis. A 2022 PMC review of published evidence and expert consensus affirms dexpanthenol as an effective and well-tolerated agent for AD flares and maintenance.

Vitamin D supplementation for atopic dermatitis is supported by a 2024 meta-analysis of 11 RCTs (686 participants) showing significant SCORAD/EASI reduction (standardized mean difference −0.41, 95% CI: −0.67 to −0.16, p<0.01). Lower serum vitamin D levels correlate with greater AD severity, and supplementation shows adjuvant therapeutic benefit.

Vitamin D3 supplementation has specific RCT evidence for atopic dermatitis. A 2020 RCT in 86 children with severe AD found D3 1600 IU/day significantly reduced EASI scores versus placebo. A 2024 meta-analysis of 11 RCTs confirmed overall significant reduction in AD severity with vitamin D supplementation.

A Mendelian randomization study found genetically predicted higher vitamin E levels significantly associated with lower risk of atopic dermatitis. Serum vitamin E levels are consistently lower in patients with chronic inflammatory skin diseases including atopic dermatitis and psoriasis. Interventional evidence in atopic dermatitis remains limited.

Atopic dermatitis and chronic eczema are listed as current modern clinical uses of X. strumarium in the Springer Nature 2026 review, reflecting transition from traditional to contemporary practice in TCM settings. Xanthatin and related compounds suppress key inflammatory mediators (IL-4, IL-5, TNF-α) implicated in atopic skin inflammation. However, it is important to note that X. strumarium itself can also cause contact dermatitis in sensitized individuals.

ESCOP formally approves external use of yarrow for mild inflammation of skin and mucous membranes. The 2017 double-blind randomized study showed yarrow oil extract restored inflamed skin parameters (capacitance, pH, erythema) at 3 and 7 days. Its sesquiterpene lactones and flavonoids inhibit inflammatory mediators in skin tissue.

Zinc has been studied in atopic dermatitis for its anti-inflammatory and barrier-supporting properties, and low serum zinc levels have been associated with AD severity. However, the AAD guidelines rate evidence as inconsistent for zinc supplementation in established AD. Topical zinc preparations (zinc oxide) are also used for irritant and diaper dermatitis.

Agrimony is traditionally used as a topical agent for skin inflammation and dermatitis, with the German Commission E and EMA HMPC monographing its use for mild skin inflammation. Astringent tannins and anti-inflammatory flavonoids provide the mechanistic basis. No controlled human trial in dermatitis exists.

A. tinctoria has been used topically for inflammatory skin diseases since classical antiquity. Hippocrates, Theophrastus, and Dioscorides all documented its use for dermatological conditions. The root's antipruritic, anti-inflammatory, and astringent properties underpin its traditional application to irritated and inflamed skin, including dermatitic conditions.

Contact dermatitis and atopic dermatitis are listed traditional indications for argan oil in Moroccan folk medicine. Anti-inflammatory and barrier-protective mechanisms are biologically plausible. Human clinical data specific to dermatitis are absent.

Barberry has documented traditional use for inflammatory skin conditions including dermatitis, used both topically and internally. Its anti-inflammatory and antimicrobial properties underpin this use across Persian, Ayurvedic, and European herbal medicine traditions.

Black tea (Camellia sinensis) tannins have been empirically used in dermatology for inflammatory skin conditions including dermatitis since ancient times. Tannins from black tea, witch hazel, and oak bark share astringent and anti-inflammatory properties recognized in official dermatological practice.

Burdock is documented in TCM and European herbalism for inflammatory skin conditions including dermatitis and contact dermatitis. Herbal Reality links burdock's anti-inflammatory mechanisms directly to supporting eczema and dermatitis. The EMA monograph recognizes its traditional use for seborrhoeic skin conditions. No dedicated clinical trials for dermatitis exist.

Clematis has traditional use in multiple cultures for chronic skin conditions including dermatitis, skin sores, and eruptions. European folk practitioners applied Clematis topically as a counter-irritant for chronic skin ailments. The anti-inflammatory properties demonstrated in animal models may underlie this use but no clinical studies address it.

Comfrey has documented traditional and some observational clinical evidence for topical use in atopic dermatitis and skin inflammation. Human clinical and observational studies have identified efficacy of external comfrey preparations for atopic dermatitis. Allantoin's anti-inflammatory and keratolytic properties are mechanistically relevant to inflammatory skin conditions including dermatitis.

CSO's phytosterols — particularly β-sitosterol — have shown anti-inflammatory activity in activated keratinocytes and macrophages relevant to dermatitis. A clinical ointment containing β-sitosterol improved management of acute dermatitis in a clinical setting (Geara et al., 2018, cited in Frontiers in Pharmacology 2025). Traditional Ayurvedic uses of CSO include addressing skin inflammation. No RCT using CSO itself for diagnosed dermatitis exists.

E. littorale is used in traditional Indian medicine for skin diseases including eczema, itching, and skin disorders associated with Pitta imbalance in Ayurveda. It is documented in Siddha medicine for skin diseases (Pitta diseases) and mentioned in folk medicine for eczema. No clinical dermatology trials have been published.

Flaxseed has documented traditional use for skin inflammation including dermatitis, referenced in historical medical texts and pharmacopeial traditions. RxList documents topical flaxseed application for 'eczema' and 'inflammation,' while modern evidence on ALA's anti-inflammatory skin properties provides mechanistic support.

Geranium EO has documented traditional use for dermatitis and contact skin inflammation. Animal model evidence demonstrates attenuation of contact dermatitis. Human clinical evidence is limited, and the use is primarily rooted in traditional practice backed by in vitro and animal data.

Goldenseal is traditionally applied to inflamed skin conditions including contact dermatitis, consistent with its documented use for skin and mucous membrane inflammation. The NCCIH notes berberine-containing plants have been used for skin diseases in traditional systems.

Hypericin, the photodynamic pigment of St. John's Wort (Hypericum perforatum), is one of the characteristic metabolites contributing to the plant's anti-inflammatory and antimicrobial effects used traditionally for dermatitis and inflammatory skin conditions. Clinical evidence centers on whole-plant hyperforin preparations rather than isolated hypericin for dermatitis.

Indian sarsaparilla is documented in Ayurveda for various inflammatory skin conditions including dermatitis, applied both topically and internally. Its anti-inflammatory, antimicrobial, and blood-purifying properties are the traditional rationale. Preclinical evidence of anti-inflammatory and antimicrobial activity provides biological plausibility.

Dermatitis (skin inflammation) is listed as a traditional use of IHN in RxList, WebMD, and related clinical compendia. Evidence is limited and pertains primarily to inositol broadly rather than IHN specifically. A 2024 systematic review on inositol for dermatological disorders found limited evidence for seborrheic dermatitis and noted that studies on IHN specifically for dermatitis are lacking.

Lecithin is used in topical skincare formulations for dermatitis based on its emollient, moisturizing, and skin-barrier properties. RxList documents this use, but evidence from controlled clinical trials in humans is absent. Use is traditional/cosmetic in nature.

Neem oil is traditionally used in Ayurveda and folk medicine for contact and seborrhoeic dermatitis, with the Dermatology Times reporting leaf juice and seed oil use for a variety of skin disorders. Antimicrobial and anti-inflammatory mechanisms are pharmacologically plausible. Human clinical trials isolating neem's effect on dermatitis specifically are lacking.

P. amurense bark is traditionally used in TCM for skin inflammatory conditions including dermatitis, characterized as 'damp-heat skin diseases.' Its immunosuppressive alkaloids (phellodendrine, berberine) reduce cutaneous delayed-type hypersensitivity. Preclinical antifungal studies also demonstrate activity against dermatophyte-associated dermatitis models. No dedicated human RCTs for dermatitis specifically with P. amurense as a standalone agent have been identified.

Plantago lanceolata is listed by the German Commission E for external use in 'inflammation of the skin,' which encompasses dermatitis. P. major leaf poultices are traditionally used for skin inflammation across European and Asian cultures. Anti-inflammatory and antioxidant compounds in the plant provide mechanistic support.

R. cordifolia is listed in multiple authoritative sources as traditionally used for dermatitis and skin ulcers. ScienceDirect notes it is 'popular all over the world for its medicinal uses in skin diseases like eczema, dermatitis and skin ulcers.' The anti-inflammatory anthraquinones are mechanistically relevant, and Ayurveda employs it for inflammatory skin conditions broadly.

Sarsaparilla has an established traditional role in treating dermatitis across multiple cultures, including TCM where it is specifically applied for dermatitis and damp-heat conditions. Astilbin's immunosuppressive properties on T-lymphocytes provide a relevant mechanistic basis. No dedicated human clinical trials for dermatitis have been published.

Scrophularia root has been used for skin inflammation and irritation across European and Asian herbal traditions, with documented use for contact dermatitis, pruritus, and inflammatory skin conditions. Traditional use is consistent across multiple species and geographic areas. Preclinical anti-inflammatory data provide a plausible basis, but no human trials exist.

Itching skin, skin diseases, and dermatitis are traditional indications for smartweed documented in Asian folk medicine. Topical poultices and leaf juice applications for inflamed and itchy skin are documented across multiple ethnomedicinal traditions.

Smilax roots have been used by Amazon shamans and indigenous practitioners for dermatitis and inflammatory skin conditions, documented in multiple ethnobotanical records. Anti-inflammatory flavonoids and saponins in the root provide a mechanistic basis, though no clinical trials in dermatitis have been conducted.

S. indicus is traditionally used in Ayurveda, Siddha, and folk medicine for allergic skin diseases and dermatitis-type conditions, with antimicrobial and anti-inflammatory properties providing mechanistic plausibility.

Tylophora has a well-documented traditional role in Ayurveda and Indian folk medicine for skin inflammatory conditions including dermatitis and rheumatism-related skin changes. Topical applications of crushed Tylophora leaves as a paste for inflamed skin and eczema-like conditions are recorded across multiple regional Indian traditions. Preclinical evidence includes anti-inflammatory and antimicrobial properties relevant to skin conditions.

White oak bark is traditionally and Commission E-endorsed for topical application in inflammatory skin conditions including dermatitis. Astringent tannins reduce skin weeping, tighten tissue, and limit secondary infection. Antioxidant and anti-inflammatory phytochemical data provide laboratory-level mechanistic support.

Witch hazel (Hamamelis virginiana) has been empirically used in dermatology since ancient times for inflammatory skin conditions including dermatitis. Its tannins provide astringent and anti-inflammatory effects on skin. It is recognized in official pharmacopeial and Commission E monographs for skin inflammation.